GlassScriptPhysician profile
Ryan Jeffrey Witt
NPI 1326450933
$14,220.89
in general payments reported to CMS, 2019-2025
20 companies · $5,415 in 2025
The $5,415 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $349 · 2021: $404 · 2022: $992 · 2023: $2,692 · 2024: $2,094 · 2025: $5,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $3,704 · Travel and Lodging: $2,479 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $3,703.74 |
| Travel and Lodging | $2,479.43 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $6,834.29 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Alcon Vision LLC | $2,932.01 | 2019-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,328.38 | 2019-2021 | |
| Abbvie INC. | $460.00 | 2022-2025 | Durysta |
| Rxsight INC | $257.52 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Allergan, INC. | $256.71 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $244.51 | 2019-2022 | |
| Biotissue Holdings INC. | $197.40 | 2025 | |
| Harrow Eye, LLC | $120.42 | 2025 | Vevye |
| Lombart Brothers, INC. | $101.16 | 2019-2025 | Opd-III |
| New World Medical,INC. | $98.62 | 2023 | |
| Coopervision INC. | $87.06 | 2019 | |
| Alimera Sciences, INC. | $75.78 | 2019 | |
| Glaukos Corporation | $53.33 | 2019 | |
| Sun Pharmaceutical Industries INC. | $48.62 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $34.37 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $27.89 | 2023 | Catalys System |
| Sight Sciences, INC. | $22.85 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.34 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $18.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.